You are welcome. I have already bought back all the shares I sold yesterday, and I have orders in to double my prior position at or near the lows today, if their is anymore selling, and if the MMs let me have more cheapies! They just let me have more at .021
I think most if not all of the day trader panic selling is over! I am amazed that the price got back down this low.
Here is some pertinent news, recent news from last month that is still useful:
Manhattan Pharmaceuticals Announces Preliminary Phase 1/2 Results for AST-915 in Essential Tremor
BY GlobeNewswire
— 7:49 AM ET 12/16/2010
NEW YORK, Dec. 16, 2010 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. announced preliminary results today from a Phase 1/2 study of AST-915 for the treatment of essential tremor. Data from this single dose study demonstrated that AST-915 was safe and well tolerated and demonstrated a clear effect on tremor power.
In this randomized, double-blind, placebo-controlled, crossover design study, 18 subjects with essential tremor received single oral doses of AST-915. Primary and secondary outcome measures included the effect on tremor power using accelerometry to test the central tremor component at various time-points after treatment. Safety, pharmacokinetic data and other efficacy measures were also evaluated. The study was conducted at The National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) under a CRADA agreement between the NIH and Ariston Pharmaceuticals, Inc., a wholly owned subsidiary of Manhattan Pharmaceuticals, Inc
----------------------------
Note this part: "The study was conducted at The National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) under a CRADA agreement"
CRADA's are typically US government partially funded research and development agreements! This one was with the NIH!!!! Are they not part of and funded by the US government? Also, MHAN got a large Federal grant of .25 to .5 million dollars in the last 8 weeks, IIRC, from the federal stimulus 2009 Act.
OK, I just checked, it is the US Government!
http://www.nih.gov/
Here is the grant, $244,xxx.xx:
http://topics.treehugger.com/article/00rJ1wZgYf5Br
I won't be surprised to see some other deals from left field here, an outside suitor with co-funding perhaps in future news.
How many other biotechs can you buy for .02/share, that have huge ownership by a European Biotech Fund (or any investment fund for that matter), and that have 4 products in the pipeline!!!!
Compare MHAN to CYTR, compare OS, and market caps, and time to market for products. Only reason MHAN stayed so low was the huge overhang of Nordic warrants and puts from any new dilution that put a cap on share prices during good news of about .08/share.
Now ask yourself why Nordic just gave MHAN (keep in mind Nordic was pissed with and fighting with MHAN over puts and warrants recently), a 1/2 million dollars and let MHAN keep part of Hedrin JV, instead of forcing MHAN to pay 1-2 million dollars to keep any of the Hedrin stake?
I am expecting more good news!
I think most if not all of the day trader panic selling is over! I am amazed that the price got back down this low.
Here is some pertinent news, recent news from last month that is still useful:
Manhattan Pharmaceuticals Announces Preliminary Phase 1/2 Results for AST-915 in Essential Tremor
BY GlobeNewswire
— 7:49 AM ET 12/16/2010
NEW YORK, Dec. 16, 2010 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. announced preliminary results today from a Phase 1/2 study of AST-915 for the treatment of essential tremor. Data from this single dose study demonstrated that AST-915 was safe and well tolerated and demonstrated a clear effect on tremor power.
In this randomized, double-blind, placebo-controlled, crossover design study, 18 subjects with essential tremor received single oral doses of AST-915. Primary and secondary outcome measures included the effect on tremor power using accelerometry to test the central tremor component at various time-points after treatment. Safety, pharmacokinetic data and other efficacy measures were also evaluated. The study was conducted at The National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) under a CRADA agreement between the NIH and Ariston Pharmaceuticals, Inc., a wholly owned subsidiary of Manhattan Pharmaceuticals, Inc
----------------------------
Note this part: "The study was conducted at The National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) under a CRADA agreement"
CRADA's are typically US government partially funded research and development agreements! This one was with the NIH!!!! Are they not part of and funded by the US government? Also, MHAN got a large Federal grant of .25 to .5 million dollars in the last 8 weeks, IIRC, from the federal stimulus 2009 Act.
OK, I just checked, it is the US Government!
http://www.nih.gov/
Here is the grant, $244,xxx.xx:
http://topics.treehugger.com/article/00rJ1wZgYf5Br
I won't be surprised to see some other deals from left field here, an outside suitor with co-funding perhaps in future news.
How many other biotechs can you buy for .02/share, that have huge ownership by a European Biotech Fund (or any investment fund for that matter), and that have 4 products in the pipeline!!!!
Compare MHAN to CYTR, compare OS, and market caps, and time to market for products. Only reason MHAN stayed so low was the huge overhang of Nordic warrants and puts from any new dilution that put a cap on share prices during good news of about .08/share.
Now ask yourself why Nordic just gave MHAN (keep in mind Nordic was pissed with and fighting with MHAN over puts and warrants recently), a 1/2 million dollars and let MHAN keep part of Hedrin JV, instead of forcing MHAN to pay 1-2 million dollars to keep any of the Hedrin stake?
I am expecting more good news!
Ambition with out knowledge is like ship in dry dock. Going nowhere fast!
Recent TGTX News
- TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI • GlobeNewswire Inc. • 04/15/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 08:33:42 PM
- TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis • GlobeNewswire Inc. • 03/09/2026 11:30:00 AM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting • GlobeNewswire Inc. • 03/06/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2026 10:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:08:34 PM
- TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
- TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis • GlobeNewswire Inc. • 02/17/2026 12:30:00 PM
- TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis • GlobeNewswire Inc. • 02/08/2026 09:17:55 PM
- TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum • GlobeNewswire Inc. • 02/06/2026 12:30:00 PM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum • GlobeNewswire Inc. • 01/27/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2026 09:27:48 PM
- TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones • GlobeNewswire Inc. • 01/13/2026 09:25:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:16:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:15:33 PM
- TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/07/2026 12:30:00 PM
- TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference • GlobeNewswire Inc. • 11/28/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/25/2025 10:31:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/24/2025 09:04:15 PM
- TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies • GlobeNewswire Inc. • 11/19/2025 01:30:00 PM
- TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit • GlobeNewswire Inc. • 11/10/2025 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2025 10:01:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/05/2025 09:31:23 PM
